Related Experiment Videos
Adrenocortical function in patients with severe atopic dermatitis
K Matsuda1, T Katsunuma, Y Iikura
1Department of Allergy, National Children's Hospital, Tokyo, Japan.
Summary
Adrenocortical suppression in severe atopic dermatitis (AD) patients may stem from topical corticosteroid absorption and other disease-related factors. Further research is needed to fully understand the causes of this complication.
Area of Science:
- Endocrinology
- Dermatology
Background:
- Topical corticosteroids are commonly used for atopic dermatitis (AD).
- Adrenocortical suppression is a known potential complication of topical corticosteroid therapy.
Purpose of the Study:
- To investigate if adrenocortical suppression in severe AD patients is solely due to topical steroid application.
- To differentiate the impact of topical corticosteroids from disease-specific factors on adrenal function.
Main Methods:
- 45 hospitalized severe AD patients were divided into two groups: those who had not used topical corticosteroids for three months (n=17) and those who used them daily (n=28).
- Adrenocortical function was assessed using rapid ACTH tests upon admission and before discharge (average 23 days later).
- Both groups received topical corticosteroids during hospitalization.
Main Results:
- Patients with severe AD exhibited significantly lower basal serum cortisol and ACTH-stimulated responses compared to controls.
- No significant differences in initial adrenal function were observed between the two pre-treatment groups.
- Following treatment, Group 1 (no prior topical steroids) showed significant improvement in morning basal serum cortisol, unlike Group 2 (daily topical steroid users).
Conclusions:
- Adrenocortical suppression in severe AD patients is likely multifactorial.
- Percutaneous absorption of topical corticosteroids contributes to adrenal suppression.
- Disease-related factors inherent to atopic dermatitis also play a role in adrenocortical dysfunction.